SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals...
Read More Details
Finally We wish PressBee provided you with enough information of ( XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS )
Also on site :
- Today’s NYT ‘Strands’ Hints, Spangram and Answers for Sunday, June 8
- At least 40 hospitalised after suspected food poisoning in western Iraq
- NYT Connections Sports Edition Today: Hints and Answers for June 8